New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 1, 2014
14:24 EDTTKPYY, JNJVelcade-based therapy 'significantly' improved progression-free survival
Millennium: The Takeda Oncology Company (TKPYY) announced results from the primary analysis of an international, randomized Phase 3 study that showed treatment with a VELCADE, bortezomib-based combination therapy demonstrated a 59% relative improvement in the study’s primary endpoint of progression-free survival among previously untreated patients with mantle cell lymphoma, MCL, compared to treatment with a standard therapy. These data were presented today at the annual meeting of the American Society of Clinical Oncology, ASCO. After a median follow up of 40 months, median overall survival, OS, a key secondary endpoint, had not been reached for patients who received the VELCADE-based therapy, while a median OS of 56.3 months was observed in patients treated with the standard regimen. Overall, among patients receiving VcR-CAP compared to R-CHOP, serious adverse events, SAEs, were reported in 38% vs. 30% of patients, and grade =3 adverse events were reported in 93% vs. 85% of patients. “The 59% relative improvement in progression-free survival, along with the trend suggesting improved OS with the VELCADE-based regimen, has the potential to represent a significant advance in the frontline treatment of mantle cell lymphoma for some patients,” said Michael Vasconcelles, MD, Global Head, Takeda Oncology Therapeutic Area Unit. “Patients with relapsed MCL have benefited from access to VELCADE therapy since 2006. We look forward to working with regulatory authorities to bring this new information to physicians and patients in the near future.” VELCADE is co-developed by Millennium/Takeda and Janssen Pharmaceutical Companies (JNJ).
News For TKPYY;JNJ From The Last 14 Days
Check below for free stories on TKPYY;JNJ the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 22, 2014
07:50 EDTJNJDoctors continue to use morcellators despite FDA warning, J&J halt, WSJ says
Subscribe for More Information
07:07 EDTJNJSynageva appoints Robert Bazemore as COO
Synageva announced the appointment of Robert Bazemore as Chief Operating Officer. Bazemore will oversee the planned global commercial launch of the company's lead program, sebelipase alfa for LAL Deficiency, and will have responsibility for the company's global commercial, market access and medical affairs operations. Bazemore last served at Johnson & Johnson (JNJ) in varoius roles including Vice President, Ethicon New Growth Platforms and President of Janssen Biotech, a part of the Janssen Pharmaceutical Companies of Johnson & Johnson.
September 17, 2014
08:36 EDTJNJJanssen-Cilag announces results from post-hoc canagliflozin analysis
Subscribe for More Information
08:12 EDTJNJJanssen-Cilag announces results from Phase 3 Invokana trial
Subscribe for More Information
September 16, 2014
07:31 EDTTKPYY, JNJEuropean Association for Study of Diabetes to hold annual meeting
50th Annual Meeting of EASD to be held in Vienna, Austria on September 15-19.
September 15, 2014
07:27 EDTJNJIBC Life Sciences to hold a conference
Subscribe for More Information
September 11, 2014
07:11 EDTJNJMedivation price target raised to $112 from $89 at Stifel
Subscribe for More Information
06:49 EDTTKPYYFDA approves weight management drug Contrave
The U.S. Food and Drug Administration yesterday approved Contrave as treatment option for chronic weight management in addition to a reduced-calorie diet and physical activity. The drug is approved for use in adults with a body mass index of 30 or greater or adults with a BMI of 27 or greater who have at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. Contrave is a combination of two FDA-approved drugs, naltrexone and bupropion, in an extended-release formulation. The effectiveness of Contrave was evaluated in multiple clinical trials that included approximately 4,500 obese and overweight patients with and without significant weight-related conditions treated for one year. Contrave is distributed by Takeda Pharmaceuticals America (TKPYY) for Orexigen Therapeutics (OREX).
September 10, 2014
10:14 EDTJNJJohnson & Johnson says off to 'very good start' this year
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use